IL133142A0 - Treatment of diabetes with thiazolidinedione and metformin - Google Patents

Treatment of diabetes with thiazolidinedione and metformin

Info

Publication number
IL133142A0
IL133142A0 IL13314298A IL13314298A IL133142A0 IL 133142 A0 IL133142 A0 IL 133142A0 IL 13314298 A IL13314298 A IL 13314298A IL 13314298 A IL13314298 A IL 13314298A IL 133142 A0 IL133142 A0 IL 133142A0
Authority
IL
Israel
Prior art keywords
thiazolidinedione
metformin
diabetes
treatment
Prior art date
Application number
IL13314298A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL133142(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL133142A0 publication Critical patent/IL133142A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13314298A 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin IL133142A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003690 WO1998057634A1 (fr) 1997-06-18 1998-06-15 Traitement du diabete a l'aide de thiazolidinedione et de metformine

Publications (1)

Publication Number Publication Date
IL133142A0 true IL133142A0 (en) 2001-03-19

Family

ID=26311745

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13314298A IL133142A0 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin
IL133142A IL133142A (en) 1997-06-18 1999-11-25 Medicinal product for the treatment of diabetes containing insulin sensitizer and biguanide anti-hyperglycemic element
IL173650A IL173650A0 (en) 1997-06-18 2006-02-09 A pharmaceutical composition for treating diabetes mellitus comprising an insulin sensitizer and a biguanide antihyperglycaemic agent

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL133142A IL133142A (en) 1997-06-18 1999-11-25 Medicinal product for the treatment of diabetes containing insulin sensitizer and biguanide anti-hyperglycemic element
IL173650A IL173650A0 (en) 1997-06-18 2006-02-09 A pharmaceutical composition for treating diabetes mellitus comprising an insulin sensitizer and a biguanide antihyperglycaemic agent

Country Status (39)

Country Link
US (3) US20060100247A1 (fr)
EP (2) EP1787646A3 (fr)
JP (1) JP2002504137A (fr)
KR (2) KR20060105005A (fr)
CN (2) CN1230171C (fr)
AP (1) AP1279A (fr)
AR (2) AR012998A1 (fr)
AT (1) ATE355840T1 (fr)
AU (1) AU8539398A (fr)
BG (2) BG109398A (fr)
BR (1) BR9810172A (fr)
CA (1) CA2294582C (fr)
CY (2) CY1107643T1 (fr)
CZ (1) CZ298469B6 (fr)
DE (2) DE69837261T2 (fr)
DK (1) DK0996444T3 (fr)
DZ (1) DZ2520A1 (fr)
EA (1) EA003144B1 (fr)
ES (1) ES2284212T3 (fr)
HK (1) HK1028193A1 (fr)
ID (1) ID23372A (fr)
IL (3) IL133142A0 (fr)
IN (1) IN189722B (fr)
LU (1) LU91356I2 (fr)
MA (1) MA26512A1 (fr)
MY (1) MY129897A (fr)
NL (1) NL300288I2 (fr)
NO (4) NO324993B1 (fr)
NZ (1) NZ501260A (fr)
OA (1) OA11516A (fr)
PE (1) PE83199A1 (fr)
PL (2) PL195140B1 (fr)
PT (1) PT996444E (fr)
SI (1) SI0996444T1 (fr)
SK (1) SK286029B6 (fr)
TR (1) TR199903057T2 (fr)
TW (1) TW565449B (fr)
UY (1) UY25049A1 (fr)
WO (1) WO1998057634A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
DE69818444T2 (de) 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
WO2000053171A1 (fr) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Utilisation de metformine dans la preparation de compositions pharmaceutiques pouvant inhiber l'enzyme dipeptidyl peptidase iv
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
EP1173434B1 (fr) 1999-04-23 2003-08-20 SmithKline Beecham plc Derive du thiazolindione et son utilisation comme antidiabetique
HU229352B1 (en) 1999-11-03 2013-11-28 Bristol Myers Squibb Co Medicament comprising the combination of metformin and glyburide
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
AU2001257456B2 (en) * 2000-05-01 2006-02-09 Aeropharm Technology, Inc. A core formulation
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
EP1738751B1 (fr) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd système de libération espacée de médicaments
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
KR20120034211A (ko) * 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1588708A4 (fr) 2003-01-29 2006-03-01 Takeda Pharmaceutical Procede pour realiser une preparation enrobee
JP4739189B2 (ja) 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
EP1772149A1 (fr) * 2004-07-27 2007-04-11 Kowa Company. Ltd. Médicament pour la prévention ou le traitement du diabète
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
KR20080028415A (ko) * 2005-07-12 2008-03-31 다이이찌 산쿄 가부시키가이샤 ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물
EP2270007A1 (fr) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. Acide 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioique, procédés de préparation et compositions avec le maléate de rosiglitazone
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
JP2012503595A (ja) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
ES2834986T3 (es) 2011-01-07 2021-06-21 Anji Pharma Us Llc Terapias basadas en ligandos de receptores quimiosensoriales
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
KR102231554B1 (ko) 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0306228B1 (fr) * 1987-09-04 1999-11-17 Beecham Group Plc Thiazolidinediones substituées
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (fr) * 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
ATE151634T1 (de) * 1991-08-26 1997-05-15 Upjohn Co Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
DK0832066T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
WO1999029314A1 (fr) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Sels de metformine et procede
EP1555845A1 (fr) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Procédé de localisation des postes d'abonnés d'un système de communication radio

Also Published As

Publication number Publication date
NO324993B1 (no) 2008-01-14
US20080090881A1 (en) 2008-04-17
NO996266L (no) 1999-12-17
UY25049A1 (es) 2000-09-29
OA11516A (en) 2004-02-04
TR199903057T2 (xx) 2000-04-21
NL300288I2 (nl) 2009-06-02
NO20090846L (no) 1999-12-17
PL337362A1 (en) 2000-08-14
EP0996444A1 (fr) 2000-05-03
SK286029B6 (sk) 2008-01-07
AP9901719A0 (en) 1999-12-31
NO20063000L (no) 1999-12-17
NO2008003I1 (no) 2008-04-21
LU91356I2 (fr) 2008-01-29
EP0996444B1 (fr) 2007-03-07
AR012995A1 (es) 2000-11-22
NL300288I1 (nl) 2007-11-01
JP2002504137A (ja) 2002-02-05
PL195140B1 (pl) 2007-08-31
IN189722B (fr) 2003-04-19
HK1028193A1 (en) 2001-02-09
PL195136B1 (pl) 2007-08-31
NZ501260A (en) 2002-09-27
SI0996444T1 (sl) 2007-08-31
EA003144B1 (ru) 2003-02-27
DE69837261T2 (de) 2007-11-08
DZ2520A1 (fr) 2003-02-01
AR012998A1 (es) 2000-11-22
EP1787646A2 (fr) 2007-05-23
CY2007018I1 (el) 2012-01-25
EA200000041A1 (ru) 2000-08-28
CN1114404C (zh) 2003-07-16
ES2284212T3 (es) 2007-11-01
AU8539398A (en) 1999-01-04
CN1429551A (zh) 2003-07-16
DK0996444T3 (da) 2007-07-02
ATE355840T1 (de) 2007-03-15
CN1260716A (zh) 2000-07-19
NO2008003I2 (no) 2010-06-28
SK179299A3 (en) 2000-11-07
BG64818B1 (bg) 2006-05-31
KR100666591B1 (ko) 2007-01-11
CA2294582C (fr) 2008-02-12
CZ9904578A3 (en) 2001-06-13
CZ298469B6 (cs) 2007-10-10
DE69837261D1 (de) 2007-04-19
KR20010013844A (ko) 2001-02-26
CY1107643T1 (el) 2012-01-25
US20060100247A1 (en) 2006-05-11
AP1279A (en) 2004-05-20
BG109398A (bg) 2006-05-31
MY129897A (en) 2007-05-31
ID23372A (id) 2000-04-20
WO1998057634A1 (fr) 1998-12-23
US20070004780A1 (en) 2007-01-04
MA26512A1 (fr) 2004-12-20
CN1230171C (zh) 2005-12-07
BR9810172A (pt) 2000-08-08
NO326958B1 (no) 2009-03-23
DE122007000054I1 (de) 2007-12-13
PT996444E (pt) 2007-06-08
TW565449B (en) 2003-12-11
NO996266D0 (no) 1999-12-17
IL133142A (en) 2006-06-11
KR20060105005A (ko) 2006-10-09
EP1787646A3 (fr) 2007-10-03
PE83199A1 (es) 1999-10-22
IL173650A0 (en) 2006-07-05
CA2294582A1 (fr) 1998-12-23
BG104060A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
IL133142A0 (en) Treatment of diabetes with thiazolidinedione and metformin
HUP0002053A3 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
HUP0003876A3 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
ZA98647B (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
AP2000001733A0 (en) Treatment of diabetes with thiazolidinedione insulin secretagogue and diguanide
PL343123A1 (en) Treatment of diabetes with rosiglitazone and insulin
IL133137A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
HK1029272A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL133907A0 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
IL133138A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
HUP0002668A3 (en) Treatment of diabetes with thiazolidinedione and metformin
HUP0002669A3 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL121656A0 (en) Diagnosis prevention and treatment of diabetes
GB9618290D0 (en) Treatment of diabetes
GB9609897D0 (en) Treatment of diabetes
GB9812314D0 (en) Treatment of diabetes